Screening for RET and ROS1 fusions in an enriched cohort of pan-negative never-smokers with advanced lung adenocarcinomas to identify patients for treatment in targeted therapy trials.
Alexander Edward Dela Cruz Drilon
No relevant relationships to disclose
Lu Wang
No relevant relationships to disclose
Adnan Hasanovic
No relevant relationships to disclose
Philippe Joubert
No relevant relationships to disclose
Mark G. Kris
No relevant relationships to disclose
Gregory J. Riely
Consultant or Advisory Role - ARIAD; Celgene; Chugai Pharma; Foundation Medicine; Novartis; Tragara Pharmaceuticals
Research Funding - Bristol-Myers Squibb; Celgene; Concordia Pharmaceuticals; GlaxoSmithKline; Infinity; Merck; Millennium; Novartis; Pfizer
Marc Ladanyi
No relevant relationships to disclose
Naiyer A. Rizvi
No relevant relationships to disclose